Latin American market expands for Raymedica's disc:
This article was originally published in Clinica
Executive Summary
Argentina, Brazil and Mexico have approved for sale Raymedica's PDN prosthetic nucleus disc device for treating low-back pain. The device has already been approved for sale in Chile and Venezuela. Latin America, where reimbursement rates for devices such as the PDN implant are equivalent to those of European countries, represents a significant market opportunity, says the Minneapolis, Minnesota firm. Argentina, Brazil and Mexico have a combined population of more than 300 million and the medical device import markets in these countries are growing at an average of 12% annually, it adds.
You may also be interested in...
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.